Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
Impel Pharmaceuticals Inc. (NASDAQ: IMPL) will host a live webcast on March 24, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. This event will also provide a business update, highlighting the company’s focus on developing transformative therapies for unmet medical needs. Impel's FDA-approved product, Trudhesa® nasal spray, is designed for acute migraine treatment. Additionally, the company continues to explore partnerships and licensing opportunities to address patient needs.
- Company will report fourth quarter and full year 2022 financial results.
- FDA-approved product Trudhesa® nasal spray targets acute migraine treatment.
- None.
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.
To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.
About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers treatments that pair its proprietary POD® technology with well-established therapeutics. In September 2021, Impel received U.S. FDA approval for its first product, Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. In addition to Trudhesa, the Company continues to address patient needs via licensing and partnerships.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com
Investor Relations
Janhavi Mohite
Stern Investor Relations
Phone: 212-362-1200
Email: janhavi.mohite@sternir.com
FAQ
When will Impel Pharmaceuticals report its financial results for 2022?
What is Trudhesa® nasal spray?
Where can I access the live webcast for Impel Pharmaceuticals' financial results?
What time is the Impel Pharmaceuticals financial results webcast scheduled for?
